Briacell Therapeutics Corp (BCTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $29.60M
Last updated: Nov 17, 2026 at 11:04 AM ET
Briacell Therapeutics Corp (BCTX) Financials: Revenue, Profit and Cash Flow
Briacell Therapeutics reported revenue of $0 for the fiscal year ended Jul 31, 2026. That year, net income was -$35.33M, operating cash flow was -$28.65M and free cash flow was -$28.78M. The quarter ended Apr 30, 2026 had revenue of $0 and net income of -$7.24M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Jul 2026, with an operating loss of $36.05M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Jul 2026 | $0 | N/A | N/A | N/A | N/A |
| Jul 2025 | $0 | N/A | N/A | N/A | N/A |
| Jul 2024 | $0 | N/A | N/A | N/A | N/A |
| Jul 2023 | $0 | N/A | N/A | N/A | N/A |
| Jul 2022 | $0 | N/A | N/A | N/A | N/A |
| Jul 2021 | $0 | N/A | N/A | N/A | N/A |
| Jul 2020 | $0 | N/A | N/A | N/A | N/A |
| Jul 2019 | $0 | N/A | N/A | N/A | N/A |
| Jul 2018 | $0 | N/A | N/A | N/A | N/A |
| Jul 2017 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Jul 2026, the net loss widened from the year before. In the quarter ended Apr 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Jul 2026 | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 | Jul 2020 | Jul 2019 | Jul 2018 | Jul 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $85.10K | $18.83K | $16.88K | N/A |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | -$85.10K | -$18.83K | -$16.88K | -$289 |
| Research and development | $29.24M | $21.27M | $27.18M | $15.34M | $8.02M | $2.02M | $2.43M | $4.94M | $3.11M | $2.12M |
| Operating income | -$36.05M | -$27.20M | -$33.33M | -$23.27M | -$15.29M | -$6.98M | -$4.02M | -$6.25M | -$4.97M | -$3.21M |
| Net income | -$35.33M | -$26.56M | -$4.93M | -$20.30M | -$26.84M | -$13.82M | -$4.02M | -$5.82M | N/A | -$3.22M |
| EBITDA | -$35.03M | -$26.23M | -$4.74M | -$20.29M | N/A | N/A | N/A | -$5.77M | N/A | N/A |
Quarterly
| Line item | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 | Jul 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $225.34K | $0 | $0 | $0 | $22.67K | $0 | $0 | $0 | $0 |
| Gross profit | $0 | -$27.14K | $0 | -$36.43K | $0 | $0 | $0 | -$71.85K | $0 | $0 | $0 | -$3.86K |
| Operating income | -$7.62M | -$7.67M | -$8.32M | -$8.55M | -$6.33M | -$7.17M | -$5.15M | -$5.77M | -$9.23M | -$9.83M | -$8.50M | -$7.71M |
| Net income | -$7.24M | -$7.35M | -$8.28M | -$8.16M | -$6.22M | -$6.34M | -$5.83M | -$1.25M | $1.69M | -$11.33M | $5.96M | -$2.42M |
Balance Sheet
As of Jul 2026, cash and equivalents of $9.85M were 41.8% of total assets of $23.58M, against total liabilities of $8.02M.
Annual
| Line item | Jul 2026 | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 | Jul 2020 | Jul 2019 | Jul 2018 | Jul 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $23.58M | $21.65M | $5.87M | $27.16M | $42.58M | $58.04M | $522.33K | $444.66K | $2.28M | $1.64M |
| Current assets | $22.04M | $19.93M | $3.65M | $26.95M | $42.35M | $57.80M | $238.95K | $165.72K | $1.88M | $1.63M |
| Cash and equivalents | $9.85M | $10.49M | $862.09K | $21.25M | $41.04M | $57.27M | $21.25K | $157.03K | $720.26K | $1.01M |
| Total liabilities | $8.02M | $4.32M | $8.56M | $30.94M | $32.25M | $30.37M | $4.12M | $1.13M | $1.34M | $885.90K |
| Short-term debt | N/A | N/A | N/A | N/A | N/A | N/A | $249.80K | $322.53K | $1.12M | N/A |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | $25.99K | $155.94K | $0 | N/A | N/A |
| Shareholder equity | $16.40M | $17.88M | -$2.38M | -$3.78M | $10.33M | $27.67M | $14.57M | $14.06M | $945.02K | $750.23K |
Quarterly
| Line item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $23.58M | $27.07M | $33.59M | $13.08M | $29.77M | $17.00M | $9.36M | $10.41M | $8.15M | $6.20M | $12.23M | $18.62M |
| Total liabilities | $8.02M | $3.66M | $3.38M | $3.72M | $5.93M | $5.06M | $6.14M | $6.70M | $11.88M | $12.44M | $20.55M | $16.10M |
| Cash and equivalents | $9.85M | $6.88M | $29.90M | $2.71M | $14.43M | $12.46M | $5.01M | $5.79M | $1.20M | $935.69K | $6.24M | $13.65M |
| Shareholder equity | $16.40M | $24.06M | $30.73M | $9.98M | $24.58M | $12.42M | $3.60M | $4.04M | -$3.31M | -$5.97M | -$8.07M | $2.72M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Jul 2026.
Annual
| Line item | Jul 2026 | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 | Jul 2020 | Jul 2019 | Jul 2018 | Jul 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$28.65M | -$28.17M | -$24.13M | -$23.74M | -$12.48M | -$7.75M | -$1.31M | -$5.12M | -$4.95M | -$1.91M |
| Capital expenditures | $127.05K | $0 | $456.80K | $0 | $0 | N/A | $0 | N/A | $3 | $4 |
| Free cash flow | -$28.78M | -$28.17M | -$24.58M | -$23.74M | -$12.48M | N/A | -$1.31M | N/A | -$4.95M | -$1.91M |
| Share repurchases | N/A | N/A | N/A | $47.29K | $10.23M | $0 | N/A | N/A | N/A | N/A |
| Investing cash flow | -$3.81M | -$7.65M | -$681.80K | $0 | $0 | $0 | $0 | $1.35M | -$590.50K | $149.85K |
| Financing cash flow | $31.81M | $45.45M | $4.42M | $3.95M | -$3.74M | $65.00M | $1.17M | $3.01M | $5.29M | $2.89M |
Quarterly
| Line item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.96M | -$7.08M | -$7.97M | -$7.70M | -$8.13M | -$7.16M | -$5.92M | -$6.96M | -$4.04M | -$5.08M | -$7.40M | -$7.61M |
| Capital expenditures | N/A | $129.18K | N/A | N/A | N/A | N/A | $0 | $0 | $624.21K | $0 | $0 | N/A |
| Free cash flow | N/A | -$7.21M | N/A | N/A | N/A | N/A | -$5.92M | -$6.96M | -$4.66M | -$5.08M | -$7.40M | N/A |
Frequently Asked Questions About BCTX
What is Briacell Therapeutics' annual revenue?
Briacell Therapeutics reported revenue of $0 for the fiscal year ended Jul 31, 2026.
Is Briacell Therapeutics profitable?
No. Briacell Therapeutics reported net income of -$35.33M for the fiscal year ended Jul 31, 2026.
How much free cash flow does BCTX generate?
For the fiscal year ended Jul 31, 2026, operating cash flow of -$28.65M minus capital expenditures of $127.05K produced free cash flow of -$28.78M.
How much debt does Briacell Therapeutics have?
The balance sheet dated Jul 31, 2026 reported cash and equivalents of $9.85M.
BCTX pages: Overview, Earnings, Financials, Competitors